


AstraZeneca

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/530,794	Applicant: Boyle et al
Filing Date: Not yet known	Attorney Docket No.: 100864-1P US
Examiner: Not yet known	Group Art Unit : Not yet known
Customer No.: 44992	Confirmation No.: Not yet known
Title: THERAPEUTIC TREATMENT	

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on December 5, 2005



Signature
Lucy Padget

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir,

Applicants submit herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

AstraZeneca R&D Boston
A business unit of AstraZeneca Pharmaceuticals LP
35 Gatehouse Drive
Waltham MA 02451
USA

Tel +1 781-839-4000
Fax +1 781-839-4500


REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed before the mailing of the **first Office Action** on the merits.

It is respectfully requested that each of the patents and publications listed on the attached Forms SB08 A and B, and other information contained herein, be considered by the Examiner and made of record in this application.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100864-1P US.


Respectfully submitted,



Name: Lucy Padget
Dated: December 5, 2005
Reg. No.: L0074
Phone No.: 781-839-4182

Global Intellectual Property, Patents
AstraZeneca R&D Boston
35, Gatehouse Drive
Waltham, MA 02451

Enclosures: Form SB08A (3 pages)
Form SB08B (2 pages)
Documents
Postcard Receipt



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number 10/530,794

Filing Date Not yet assigned

First Named Inventor Boyle, Francis Thomas

Art Unit Not yet assigned

Examiner Name Not yet assigned

Attorney Docket No. 100864-1P US

SHEET 1 of 5

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	US1	US- 5,464,853	11-07-1995	ImmunoPharmaceuticals, Inc.	
	US2	US- 5,514,691	05-07-1996	ImmunoPharmaceuticals, Inc.	
	US3	US- 2002/0055457	05-09-2002	Janus, Todd J.	
	US4	US- 5,843,902	12-01-1998	Praecis Pharmaceuticals, Inc.	
	US5	US- 2005/0014769	01-20-2005	Osswald, Mathias	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	AA	EP 510,526 A1 +English Abstract	10-28-1992	F. Hoffmann-La Roche & Co.		<input type="checkbox"/>
	AB	EP 526,708 A1 +English Abstract	02-10-1993	F. Hoffmann-La Roche AG		<input type="checkbox"/>
	AC	EP 558,258 A1	09-01-1993	E.R. Squibb & Sons, Inc.		<input type="checkbox"/>
	AD	EP 569,193 A1	11-10-1993	E.R. Squibb & Sons, Inc.		<input type="checkbox"/>
	AE	EP 640,596 A1	03-01-1995	Bristol-Myers Squibb Company		<input type="checkbox"/>
	AF	WO 96/09818 A1	04-04-1996	Merck & Co., Inc.		<input type="checkbox"/>
	AG	WO 94/27979 A1	12-08-1994	Immunopharma- ceutics, Inc.		<input type="checkbox"/>
	AH	WO 99/48530 A1	09-30-1999	Merck & Co., Inc.		<input type="checkbox"/>
	AI	WO 99/56761 A1	11-11-1999	Davar, Gudarz		<input type="checkbox"/>
	AJ	WO 00/21509 A2	04-20-2000	Imperial College Innovations Limited		<input type="checkbox"/>
	AK	WO 00/36918 A1	06-29-2000	Marine Polymers Technologies, Inc.		<input type="checkbox"/>
	AL	WO 01/00198 A2	01-04-2001	California Institute of Technology		<input type="checkbox"/>
	AM	WO 00/67024 A1	11-09-2000	New York University		<input type="checkbox"/>
	AN	WO 01/91736 A2	12-06-2001	Warner-Lambert Company		<input type="checkbox"/>

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/530,794
Filing Date	Not yet assigned
First Named Inventor	Boyle, Francis Thomas
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100864-1P US

SHEET 2 of 5

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	AO	WO 02/11713 A2	02-14-2002	Abbott Laboratories		<input type="checkbox"/>
	AP	WO 02/069906 A2	09-12-2002	Cellegy Pharmaceuticals Inc.		<input type="checkbox"/>
	AQ	WO 02/074034 A2	09-26-2002	Boehringer Ingelheim Pharma KG		<input type="checkbox"/>
	AR	WO 02/80960 A2	10-17-2002	Medical Research Council		<input type="checkbox"/>
	AS	WO 02/085351 A1	10-31-2002	Abbott Laboratories		<input type="checkbox"/>
	AT	WO 03/006041 A1 +English Abstract	01-23-2003	Takeda Chemical Industries, Ltd.		<input type="checkbox"/>
	AU	WO 03/009805 A2	02-06-2003	Brigham & Women's Hospital, Inc.		<input type="checkbox"/>
	AV	WO 03/015820 A1 +English Abstract	02-27-2003	Takeda Chemical Industries, Ltd.		<input type="checkbox"/>
	AW	WO 03/039539 A2	05-15-2003	Merck Patent GMBH		<input type="checkbox"/>
	AX	WO 03/045434 A2	06-05-2003	The Board of Trustees of the University of Illinois		<input type="checkbox"/>
	AY	WO 95/26957 A1	10-12-1995	Zeneca Limited		<input type="checkbox"/>
	AZ	EP 682,016 A1	11-15-1995	AstraZeneca AB		<input type="checkbox"/>
	BA	GB 2,295,616 A	06-05-1996	Zeneca Limited		<input type="checkbox"/>

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/530,794
Filing Date	Not yet assigned
First Named Inventor	Boyle, Francis Thomas
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100864-1P US

SHEET 3 of 5

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BB	EP 749,964 A1	12-27-1996	Zeneca Limited		<input type="checkbox"/>
	BC	WO 98/40332	09-17-1998	Zeneca Limited		<input type="checkbox"/>
	BD	EP 1 256,344 A1	11-13-2002	Yamanouchi Pharmaceutical Co. Ltd.		<input type="checkbox"/>
	BE	WO 96/40681 A1	12-19-1996	Zeneca Limited		<input type="checkbox"/>
	BF	WO 2004/018044 A2	03-04-2004	AstraZeneca AB		<input type="checkbox"/>
	BG	WO 2004/032922 A1	04-22-2004	AstraZeneca AB		<input type="checkbox"/>
	BH	WO 2005/023264 A1	03-17-2005	AstraZeneca AB		<input type="checkbox"/>
	BI	WO 2005/080403 A2	09-01-2005	AstraZeneca AB		<input type="checkbox"/>
	BJ	WO 01/60370 A1 and English equivalent EP1256344	08-23-2001	Yamanouchi Pharmaceutical Co. Ltd.		<input type="checkbox"/>
	BK	WO 02/49630 A2	06-27-2002	Bristol-Myers Squibb Company		<input type="checkbox"/>
	BL	WO 01/44239 A2	06-21-2001	Bristol-Myers Squibb Company		<input type="checkbox"/>
Examiner Signature				Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

SHEET 4 of 5

Complete if Known

Application Number	10/530,794
Filing Date	Not yet assigned
First Named Inventor	Boyle, Francis Thomas
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100864-1P US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	NELSON JB "Endothelin-1 Production and Decreased endothelin B Receptor Expression in advanced Prostate Cancer" Cancer Research 56, 663-668, February 15, 1996	<input type="checkbox"/>
	AB	KROODSMA JM; <i>et al</i> "Endothelinen: mogelijk een nieuw farmacologisch aangrijpingspunt bij hart-en vaatziekten, nierziekten en oncologische aandoeningen" Nederlands Tijdschrift Voor Geneeskunde, 1997 Sept 20, 141, 38, 1806-10 +English Abstract	<input type="checkbox"/>
	AC	An abstract reporting the symposium "Endothelin Inhibitors: Exploring Novel Therapeutics" Meeting Report (June 25, 1999) Washington DC, USA, June 7-8 1999	<input type="checkbox"/>
	AD	BOVEN E An abstract by reporting from the "American Society of Clinical Oncology - 35 th Annual Meeting (Part I)" Meeting Report (Sept 13, 2001), Atlanta, GA, USA, May 15-18 1999	<input type="checkbox"/>
	AE	MCKINNON C An abstract by reporting from the "American Society of Clinical Oncology - 35 th Annual Meeting (Part IV)" Meeting Report (Sept 13, 2001), Atlanta, GA, USA, May 15-18 1999	<input type="checkbox"/>
	AF	ADENIYI A An abstract by reporting from the "American Urological Association - 94 th Annual Meeting" Meeting Report (Aug 26, 1999), Dallas, TX, USA, May 1-6 1999	<input type="checkbox"/>
	AG	BOVEN E "American Society of Clinical Oncology - 35 th Annual Meeting" IDrugs, (1999) 2/7 (617-619), Atlanta, GA, USA, May 15-18 1999	<input type="checkbox"/>
	AH	MCKINNON C "Topoisomerase Inhibitors and Other New Agents", IDrugs, (1999) 2/7 (629-632) Atlanta, GA, USA, May 15-18 1999	<input type="checkbox"/>
	AI	ADENIYI A "American Urological Association - 94 th Annual Meeting" IDrugs, (1999) 2/7 (656-658), Dallas, TX, USA, May 1-6 1999	<input type="checkbox"/>
	AJ	NELSON JB "Editorial: Endothelin Receptor Antagonists in the Treatment of Prostate Cancer" The Prostate 49: 91-92 (2001) Pittsburgh, PA USA	<input type="checkbox"/>
	AK	NELSON JB; <i>et al</i> "The Role of the Endothelin Axis in Prostate Cancer" The Prostate Journal. Volume 1, Number 3, May / June 1999, 126-130	<input type="checkbox"/>
	AL	NELSON JA; <i>et al</i> "Identification of Endothelin-1 in the Pathophysiology of Metastatic Adenocarcinoma of the Prostate" Nature Medicine, Vol 1, No 9, September 1995, 944-949	<input type="checkbox"/>
	AM	CURWEN JO; <i>et al</i> "ZD4054: A Specific Endothelin a Receptor Antagonist with Potential Utility in Prostate Cancer and Metastatic Bone Disease" EORTC-NCI-AACR, Frankfurt, Germany AstraZeneca Poster presented 19-22 November 2002	<input type="checkbox"/>
	AN	BAGNATO A; <i>et al</i> "Autocrine Actions of Endothelin-1 as a Growth Factor in Human Ovarian Carcinoma Cells" Clinical Cancer Research, 1995, Vol 1, 1059-1066	<input type="checkbox"/>
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/530,794
Filing Date	Not yet assigned
First Named Inventor	Boyle, Francis Thomas
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100864-1P US

SHEET 5 of 5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AO	CARDUCCI MA; <i>et al</i> "Endothelin Receptor Antagonist: ABT-627 Prostate Cancer: Initial Trial Results" The Journal of Urology, Vol. 161, no. 4, SUPPL, April 1999, page 176, Baltimore, MD, USA	<input type="checkbox"/>
	AP	DERWENT AN 2001-565331, XP002271565	<input type="checkbox"/>
	AQ	JARVIS MF; <i>et al</i> "ABT-627, an Endothelin ET _A Receptor-Selective Antagonist, Attenuates Tactile Allodynia in a Diabetic Rat Model of Neuropathic Pain" European Journal of Pharmacology, 2000, Vol 388, 29-35, Abbott Park, IL USA	<input type="checkbox"/>
	AR	WU-WONG JR "Endothelin Attenuates Apoptosis in Human Smooth Muscle Cells" Biochemical Journal, 1997, Vol 328, No. 3, 733-737, Abbott Park, IL USA	<input type="checkbox"/>
	AS	SPINELLA, F "Endothelin-1 Induces Vascular Endothelial Growth Factor by Increasing Hypoxia-Inducible Factor-1a in Ovarian Carcinoma Cells*" J Biological Chemistry, 2002, 277 (31), 27850-27855, Rome Italy	<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.